Johnson & Johnson $(JNJ)$ shares rose 0.4% in premarket trades after the medical-technology and drug company beat Wall Street's profit and revenue estimates and raised its full-year sales guidance.
Johnson & Johnson reported per-share earnings of $4.54 for the quarter, which includes the reversal of special charges, up from $1.34 a share in the prior year's quarter.
Adjusted for one-time items, EPS came to $2.77 a share, above the $2.58 FactSet consensus.
Sales rose 2.4% to $21.893 billion, above the FactSet consensus of $21.559 billion. The New Brunswick, N.J.-based company raised its full-year operational sales guidance to a range of $91.6 billion to $92.4 billion, from its prior outlook of $90.9 billion to $91.7 billion. Johnson & Johnson said that this reflects the addition of the CAPLYTA medication for treating bi-polar depression following the completion of the Intra-Cellular Therapies acquisition.
In a separate announcement, Johnson & Johnson announced a 4.8% increase in its quarterly dividend, from $1.24 to $1.30 a share. The raised marked the 63rd year of consecutive dividend raises, the company said.
(This is a developing news story with updates to come.)
-James Rogers
For more from MarketWatch: http://www.marketwatch.com/newsviewer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 15, 2025 06:48 ET (10:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。